Objective: To examine ambient isoflurane pollution, scavenging efficacy, and isoflurane consumption using the Anesthetic Conserving Device (ACD) for prolonged isoflurane sedation in the intensive care unit.
I nhalational agents represent an alternative to commonly used intravenous drugs for sedation of ventilator-dependent patients in the intensive care unit (ICU). They are easily titrated as the drug concentration can be followed on-line with end-tidal gas concentration monitoring. Several studies indicate a more rapid emergence after brief or prolonged sedation with inhala-tional agents compared with common intravenous agents (1) (2) (3) (4) .
Isoflurane is a widely used anesthetic agent which to large extent (99.8 %) is eliminated in unchanged form via exhalation after discontinued administration-thus elimination of active drug is largely independent of renal or liver function (5) . Isoflurane has been used previously for ICU sedation (1) (2) 6) in studies performed with delivery of isoflurane through vaporizers using adapted highflow ICU ventilators. Vaporizers are not standard equipment in most modern ICUs, and gas consumption with highflow systems is relatively high. Excessive agent consumption and concerns about environmental contamination may partly explain why sedation with inhalational agents has not become established as a standard treatment in the ICU setting (7) .
The Anesthetic Conserving Device (ACD/AnaConDa, Sedana Medical, Sundbyberg, Sweden, Fig. 1 ) is a modified heat-moisture exchanger. The ACD is fit-ted at the endotracheal tube and adapted for direct infusion of anesthetic agent to an evaporator rod in the ACD, whereby isoflurane is delivered at each inhalation. Additionally, a lipophilic carbon particle filter in the ACD promotes rebreathing (via adsorption-desorption) of approximately 90% of exhaled anesthetic agent. Consequently, only a small amount of anesthetic gas escapes the system, with theoretically low ambient pollution and isoflurane consumption similar to that seen with low-flow circle systems (8) . The feasibility of using the ACD as a delivery system for anesthetic agents has been confirmed in studies in the operating room environment (8, 9) .
A randomized controlled efficacy study comparing isoflurane via the ACD to intravenous midazolam for sedation of ventilator-dependent ICU patients was conducted at the general ICU at the Karolinska University Hospital in Stockholm 2002 Stockholm -2003 . To our knowledge, this was the first study of the ACD in the ICU setting.
This novel technique of administering isoflurane requires different handling routines than with traditional vaporizer administration. The degree of ambient isoflurane pollution when using the ACD for sedation in the ICU setting has not been previously examined. Although inhalational sedation with the ACD may provide a novel alternative to intravenous agents, concerns about environmental exposure must first be addressed. Moreover, theoretically low isoflurane consumption for sedation with this method has not yet been confirmed.
We therefore conducted a prospective, observational study of 15 patients sedated with isoflurane via the ACD to evaluate ambient isoflurane pollution and isoflurane consumption during sedation with the ACD.
MATERIALS AND METHODS

Patients
The study was conducted at the general ICU at the Karolinska University Hospital Solna, Stockholm, Sweden. The study was approved by the Karolinska Institute Local Ethics Committee for Human Research. Patients between ages 18 and 80 who were expected to require mechanical ventilation and sedation for Ͼ12 hrs were eligible to receive isoflurane sedation via the ACD. Patients were excluded from the study if there was any evidence of intracranial pathology, family history of malignant hyperthermia, need for dialysis at inclusion, or pregnancy or if continuous sedation had been administered for Ͼ18 hrs before inclusion. The 15 patients studied were among the first to be sedated with isoflurane via the ACD in our ICU. Patients were sedated with isoflurane until extubation or for a maximum of 4 days, as previous experience for longer periods is limited.
Interventions
Patients were ventilated with the Siemens Servo 300 ventilator (Siemens-Elema/Maquet, Solna, Sweden) or the Dräger Evita 4 ventilator (Dräger Medical AG KgaA, Lübeck, Germany). Isoflurane syringes were prefilled outside the ICU with a closed bottle technique. Isoflurane was infused via a standard ICU syringe pump (P6002/TIVA, Alaris Medical Systems, Sollentuna, Sweden) to the evaporator rod in the ACD and inhaled. The infusion rate was initially chosen according to the patient's minute ventilation and manufacturer nomogram and then adjusted to reach adequate sedation. The sedation end point was to keep patients sedated within the Ϫ1 to ϩ1 interval on the Bloomsbury Sedation Score (Table 1 ) (10) . Isoflurane was used as the only continuous sedative during the study. Sedation depth was increased and decreased by changing the isoflurane infusion rate. When needed, a bolus dose of isoflurane was given by increasing the infusion rate to 10 mL/hr for 2 mins. If this bolus dose was not sufficient or if the patient needed a rapid increase of sedation, propofol 0.5 mg/kg was given. Morphine for analgesia was given by infusion or intermittently according to the ICU physician's orders.
Nursing staff was given a brief introduction to isoflurane sedation and the ACD by the investigators before starting the study. This included instructions for standardizing procedures such as disconnection of the ACD for suctioning and nebulization of drugs.
During isoflurane sedation, three procedures required opening of the closed isoflurane delivery system:
Nebulization of Drugs/Endotracheal Suctioning. The respiratory circuit was opened on the "high concentration" side of the ACD and the nebulizer placed between the endotracheal tube and the ACD (according to the manufacturer's instructions) such that nebulized drug did not pass through the ACD before reaching the patient. For the brief disconnection when adding a nebulizer to the circuit, the ventilator was placed in standby mode or on expiratory hold. During suctioning of the patient's endotracheal tube, the ACD was sealed temporarily with a lid provided with the ACD, and the ventilator was placed in standby mode.
Replacing the Isoflurane Syringe. The isoflurane syringe was changed by pausing the isoflurane infusion and removing and capping the infusion catheter from the empty syringe while the syringe remained in the pump. After the empty syringe was capped and removed, a filled syringe was placed in the syringe pump. The infusion catheter was then connected to the new syringe, and the infusion was restarted at the same rate as before the change.
Replacing the ACD. The ACD was replaced once daily by the investigators. The ACD has a permanently fixed infusion catheter, which was disconnected from the syringe in the syringe pump and capped. The infusion catheter of a new ACD was connected to the syringe. After the newly connected infusion catheter was filled with a bolus equal to its internal volume (1.2 mL), the used ACD was replaced in the respiratory circuit with the new, "isoflurane-primed" ACD, the ventilator having been set in standby mode or on expiratory hold. Finally, the infusion of isoflurane was restarted and the used ACD was sealed. Occasionally, the infusion rate needed to be increased temporarily after changing the ACD.
Isoflurane administration was terminated by removal of the ACD from the circuit, either when patients were ready for extubation or after 4 days of isoflurane sedation.
The ICU rooms in the study were three-bed rooms including a small nurse's station. The total room volume in each ICU room is 130 m 3 . The hourly ventilation in these rooms is 600 m 3 /hr, the equivalent of 4 air changes/hr. Our ICU is equipped with passive wall outlets at each bed connected to the hospital waste gas system. Ventilation waste gases are generally not evacuated actively. For this study, the ventilator was connected to the hospital waste gas system wall outlet. To move the gas from the ventilator to the wall outlet, an ejector suction device using separate air supply was placed in the scavenging system (Figs. 2 and 3). Sample gas diverted from the breathing circuit to the gas monitor was also led into the scavenging system.
This scavenging system was used for the first ten patients. As the baseline levels monitored on-line were well below recommended exposure limits, we decided to follow the ambient isoflurane levels in five patients without the scavenging system connected. For these five patients it was decided that the scavenging system would be connected if isoflurane levels reached 5 ppm, half the Swedish recommended long-term exposure limit.
Measurements
Isoflurane contamination was measured with two methods: continuous spectrophotometry and passive lapel dosimeter sampling. Continuous measurements provided a general idea of background pollution as well as the frequency, magnitude, and duration of peaks in relation to various interventions. Dosimeter measurements are most useful for comparisons of staff exposure with recommended occupational exposure limits.
Continuous measurement of the ambient air concentration of isoflurane was performed with an infrared spectrophotometer (Miran 1 B, Foxboro, South Norwalk, CT) calibrated for measuring isoflurane. The sampling probe was placed above the patient's head at 0.5 m from the ACD to approximate nursing staff exposure. Isoflurane concentration in parts per million (ppm) was displayed on-line on the spectrophotometer bedside and simulta-neously printed as a curve on a monitoring sheet at 1 mm/min speed (Fig. 4) .
The ppm value was noted hourly by the staff nurse on duty, and all disconnections of the respiratory circuit, isoflurane syringe changes, and ACD changes were registered and later evaluated for correlation with measured isoflurane peaks. In the analysis of the isoflurane concentration curves, all periods lasting Ͼ10 mins with time-weighted average values Ͼ2 ppm (one tenth of the Swedish short-term limit) were noted. Furthermore, all peaks above 5 ppm lasting for Ͼ1 min (half the Swedish long-term limit) were noted.
Ten passive lapel dosimeters (SKC Passive Sampler 575-002, Eighty Four, PA) were used during the study. The dosimeters were distributed to ten different nurses working different shifts during the course of the study to ensure a variety of users and working hours (day/ evening/night). These nurses cared for four of the study patients, all of whom were studied with an active evacuation system. The nurses in our ICU work according to a primary nursing system and spend most of their shift near the patient. The dosimeters were kept open for 8 hrs of patient care, excluding breaks. They were later analyzed with gas chromatography at the Unit of Occupational and Environmental Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
The infusion rate of isoflurane was recorded for each patient, as were boluses of isoflurane given to increase depth of sedation. Inspired and end-tidal fraction of isoflurane was measured continuously (Datex-Ohmeda AS 3 Compact, Dansjö Medical, Stockholm AB, Sweden) and noted hourly. Bolus doses of propofol were also noted, as were morphine infusions and bolus doses.
RESULTS
Patients included in the study are described in Table 2 . Patients were sedated with isoflurane for varying lengths of time (Table 3) . Eight patients were extubated during isoflurane sedation. One patient received a tracheostomy and sedation was terminated, one patient was transferred to another ICU during the course of the study, and one patient died during the study. In the remaining four patients, isoflurane sedation was terminated after 4 days and replaced with another sedative at the discretion of the treating ICU physician.
Both stationary sampling and personal monitoring (Tables 4 and 5) showed low degrees of ambient isoflurane pollution during ACD-delivered isoflurane sedation.
The infrared-spectrophotometry revealed low exposure levels in all patients, with an average value of 0.1 ppm (n ϭ 15, range 0.0 -0.5 ppm). Isoflurane peaks were infrequent, of short duration, and below the Swedish recommended shortterm exposure limit for ambient isoflurane concentration (n ϭ 13, due to printer failure in two patients, Table 6 ). The ambient isoflurane pollution level was low even in patients without the scavenging system as seen in Table 1 .
Isoflurane consumption averaged 2.1 Ϯ 1.0 mL/hr (range 0.82-5.0 mL/hr) as seen in Table 3 . The infusion rate was generally slightly higher during initiation of sedation and could often be decreased after a few hours. The range of infusion rates was quite narrow with the exception of one patient who required a somewhat higher end-tidal concentration to achieve adequate sedation.
DISCUSSION
To our knowledge, this is the first study of the environmental aspects of isoflurane sedation with the ACD in the ICU setting. In the present ICU setting, our results indicate low levels of ambient isoflurane, supporting the theoretical environmental safety of this new administration method for isoflurane, and agent consumption considerably less than previously described with vaporizer technique. These practical aspects may make inhalational sedation a more feasible and attractive alternative to intravenous sedation in ICU practice.
The peaks of isoflurane leakage were low and brief with few events causing isoflurane levels to reach the lowest recommended working exposure limit used in the United States (Table 6 ). This limit is considerably more stringent than most European recommendations. The U.S. general recommendation of 2 ppm for halogenated agents from 1977 (before the introduction of isoflurane) has since been revised for halothane and enflurane, with new long-term limits of 50 ppm and 75 ppm, respectively. New recommendations for isoflurane may also be forthcoming.
Lapel dosimeter readings (Table 5 ) were well below national and international recommended long-term exposure limits. Levels appeared to be slightly higher during day shifts, possibly reflecting more frequent circuit interruptions and interventions.
Studies of environmental contamination in the ICU have been performed previously during isoflurane sedation using traditional vaporizer technique (11, 12) . These studies showed low ambient isoflurane pollution values when active scavenging systems were used.
A clear learning curve among users was observed in our study. After six patients were sedated with the new method (three pilot patients and three study patients), the investigators and staff had become comfortable in handling the equipment, and unnecessary loss of isoflurane or prolonged opening of the breathing circuit could be avoided. This was reflected in the measured isoflurane peaks during the course of the study.
The fact that levels did not increase after active scavenging was eliminated indicates that the standard ventilation (4 air exchanges/hr, 600 m 3 /hr) in our ICU is sufficient to keep levels well below recommended limits. This ventilation rate is approximately twice the Swedish recommended minimum ventilation. The rebreathing function of the ACD substantially reduces the fraction of isoflurane in the exhaled air in the expiratory limb beyond the ACD, resulting in a much lower fraction of isoflurane in the waste gas compared with conventional vaporizer technique with high-flow ventilators.
Many studies investigating the risks of occupational exposure to inhalational agents have been performed since their introduction, with widely varying results (13, 14) . In general, reduced fertility in females occupationally exposed to nitrous oxide or inhalational anesthetics has been described in some retrospective studies (15, 16) , whereas prospective and register studies have failed to show such an association (17, 18) . Little evidence for clinically significant teratogenic effects of isoflurane exposure can be found. Exposure of pregnant mice to isoflurane for 4 hrs/day on gestational days 6 -15 caused decreased fetal weight and congenital malformations but only at 6000 ppm, whereas no effects were seen at 60 or even 600 ppm (19) . Mutagenic or carcinogenic potential of trace concentrations of modern inhalational agents appears to be low or nonexistent (13) .
Despite little evidence for hazards of occupational exposure below recommended limits, there may be concern among staff exposed to isoflurane and other inhaled anesthetic agents, and it is good practice to minimize ambient isoflurane pollution when working with and administering the agent.
Consumption of isoflurane was low in the study patients, supporting the proposed agent rebreathing property of the ACD. In an earlier study of isoflurane sedation in ICU patients with median end-tidal isoflurane concentration of 0.35%, the median hourly consumption was 9.6 mL (2). Assuming a minute ventilation of 7.5 L and an inspired isoflurane concentration of 0.3%, calculated isoflurane requirement with a high-flow ventilator would be 8 mL/hr. Given these data, the present system appears to result in a 75% reduction in agent consumption compared with vaporizer and high-flow circuit systems, making it an economically feasible alternative from an agent expenditure perspective. Similarly, sevoflurane consumption with the ACD in the operating room setting was similar to that of a low-flow (1-1.5 L/min) conventional semiclosed circle system (8) .
Although attractive from an agent consumption perspective, routine use of the ACD may imply other ICU costs, such as use of gas monitoring equipment. Most newer ICU ventilators do not have vaporizer adapters; in the near future, the only alternatives for inhalational agent use in the ICU may be a nonvaporizer system like the ACD or an anesthesia machine. Although modern anesthesia machines have increasingly sophisticated ventilator functions, the ACD may be practically simpler than moving large anesthesia machines from the operating room to the ICU. It may also be conceptually simpler than an anesthesia machine for non-anesthesiatrained physicians and nursing staff. Sedative dosage via the ACD is adjusted by changing an infusion rate, which is analogous to intravenous sedatives.
Limitations
Our study results reflect sedation of one patient at a time in our unique ICU setting (room size, ventilation, scavenging system). The probable degree of pollution in a given ICU setting can be predicted given these factors and the isoflurane-saving characteristics of the ACD that were confirmed in this study. Although relatively low isoflurane concentrations seem adequate for sedation, the ACD can be used to provide general anesthesia, and environmental pollution may increase somewhat with increasing gas concentration or with more widespread use in the ICU. Generalization of the results of our study must be made with caution, taking these factors into account. Although closed suctioning systems are not presently used in our unit, such a system would result in fewer circuit interruptions and probably would reduce isoflurane pollution levels further.
CONCLUSIONS
The use of the ACD for isoflurane sedation in the ICU appears to be environmentally safe with a low degree of isoflurane pollution, provided users follow instructions for standardizing routines in handling equipment and isoflurane. Although long-term working limits need not be exceeded in the absence of active evacuation systems, scavenging is recommended. Initial on-line monitoring of ambient isoflurane pollution may give feedback to users in understanding potential causes of isoflurane leakage and help reduce the risk of unnecessary isoflurane exposure among staff. The use of the ACD appears to reduce isoflurane consumption substantially when compared with isoflurane sedation via vaporizers and high-flow ventilators.
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